Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Translate Bio

https://translate.bio/

Latest From Translate Bio

CEO Of India's mRNA Pioneer Gennova On Cancer Vaccines, VC Interest

Founder CEO Sanjay Singh tells Scrip about Gennova Biopharma's preliminary talks with investors looking to grab a piece of the action post approval of its mRNA vaccine against COVID-19. As the company considers use of the technology in making vaccines against cancer and infectious diseases, it will also expand manufacturing

Commercial Coronavirus COVID-19

Juicy Apples Come From Healthy Trees: Advice For Platform Developers

Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.

Innovation Platform Technologies

Sanofi’s Triomphe On Vaccine Plants Of The Future, Regulatory Speed

Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.

Commercial Singapore

Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Growth Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • RaNA Therapeutics Inc.
UsernamePublicRestriction

Register